标题
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
作者
关键词
-
出版物
Nature Communications
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-11-18
DOI
10.1038/s41467-021-27093-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
- (2021) Ariella B. Hanker et al. CANCER CELL
- Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu–Driven Tumorigenesis
- (2019) Zachary L. Watson et al. CANCER RESEARCH
- Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance
- (2019) Alex Pearson et al. CLINICAL CANCER RESEARCH
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
- (2019) Lillian M. Smyth et al. Cancer Discovery
- Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
- (2018) Luca Gianni et al. LANCET ONCOLOGY
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
- (2018) Emiliano Cocco et al. Science Signaling
- Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
- (2017) Mateus de Oliveira Taveira et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- HER2-positive breast cancer is lost in translation: time for patient-centered research
- (2017) Isabelle Gingras et al. Nature Reviews Clinical Oncology
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
- (2016) Shom Goel et al. CANCER CELL
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
- (2016) Ronglai Shen et al. NUCLEIC ACIDS RESEARCH
- Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
- (2016) Saya H. Ebbesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- (2014) Moriah H. Nissan et al. CANCER RESEARCH
- An Optimized microRNA Backbone for Effective Single-Copy RNAi
- (2013) Christof Fellmann et al. Cell Reports
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Cooperative Activation of PI3K by Ras and Rho Family Small GTPases
- (2012) Hee Won Yang et al. MOLECULAR CELL
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
- (2009) T. W. Miller et al. CLINICAL CANCER RESEARCH
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells
- (2008) A. Vazquez-Martin et al. ANNALS OF ONCOLOGY
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started